Pharmacoscan-microarray-solution

 

A variety of PGx solutions for your individual needs

Pharmacogenomics helps us to understand why individuals respond differently to medicines. This field of science and genomics allows us to predict an individual’s response to a drug, allowing us to select medications over others. It also has the potential to help develop effective, safe medications and doses tailored to an individual’s genetic makeup.

In 2019, over 260 drugs discuss pharmacogenetics on their FDA labels (1), with well over 20,0000 publications referencing this important area of science.

Thermo Fisher Scientific has been developing pharmacogenomic solutions across multiple genetic platforms since 2014. If you need help selecting the right solution for your laboratory needs, use the selection guide below or have a technical representative contact you.

Select the right solution for your pharmacogenomic needs:

Need more help selecting the right pharmacogenomic technology? Contact a technical representative ›

I want a flexible, scalable, qualified solution for routine testing and more. I want to discover new biomarkers and variants. I want the maximum amount of data available from my sample.
Optimized for routine testing and preemptive analysis using actionable markers Excellent for new biomarker and variant discovery Best positioned for research and development, preemptive analysis of all known markers
See Real-time PCR solution for pharmacogenomics See Ion AmpliSeq PGx solution See Axiom microarray solutions

Which solution is right for me?

 

Real-time PCR solution for pharmacogenomics Ion AmpliSeq PGx solution Axiom microarray solutions

Technology

Real-time PCR with TaqMan Assays

Next-generation sequencing with Ion AmpliSeq technology

Microarray with Axiom assays

Number of targets

Up to 120

Over 120

4,627 markers in 1,191 genes

Turnaround time

~ 5 hours

~ 36 hours

~ 5 days

Other features

  • Low-cost per sample
  • Scalable, from single gene to panel screening
  • Qualified solution with over 7 million samples tested to date, launched in 2012

 

  • Complete, integrated solution from sample to results with optimized protocols
  • Variant discovery and broad panel screening
  • Robust assays

 

  • Cost-effective, reproducible, and scalable solution for translational researchers
  • Developed in collaboration with experts from CPIC, PharmaADME, and PharmGKB

 


Learn more: the latest in pharmacogenomics

Article
waiting-room

Hear how Coriell Life Sciences, the Personalized Medicine Coalition, and other precision medicine experts discuss the progress made in pharmacogenomics.